SERS liquid biopsy: An emerging tool for medical diagnosis

Moisoiu, Vlad; Iancu, Ștefania D.; Ştefancu, Andrei; Moisoiu, Tudor; Pardini, Barbara; Dragomir, Mihnea P.; Crişan, Nicolae; Avram, Lucreția; Crişan, Dana; Andraș, Iulia; Fodor, Daniela; Leopold, Loredana; Socaciu, Carmen; Bálint, Zoltán; Tomuleasa, Ciprian; Elec, Florin Ioan; Leopold, Nicolae

doi:10.1016/j.colsurfb.2021.112064

Cited by 54 publications

(38 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These Raman spectra contain abundant molecular information, reflecting the chemical and pathological state of cells or tissues [ 71 ]. So far, direct SERS has been applied for food safety testing, field testing, liquid biopsy and cancer diagnosis [ 67 , [72] , [73] , [74] ]. For the indirect strategies, NPs modified with Raman reporters are used as labels to specifically bind to targets, e.g., protein biomarkers.…”

Section: Main Metabolic Molecules Detecting Methodsmentioning

confidence: 99%

Human metabolite detection by surface-enhanced Raman spectroscopy

Liu

2022

Materials Today Bio

View full text Add to dashboard Cite

Metabolites are important biomarkers in human body fluids, conveying direct information of cellular activities and physical conditions. Metabolite detection has long been a research hotspot in the field of biology and medicine. Surface-enhanced Raman spectroscopy (SERS), based on the molecular “fingerprint” of Raman spectrum and the enormous signal enhancement (down to a single-molecule level) by plasmonic nanomaterials, has proven to be a novel and powerful tool for metabolite detection. SERS provides favorable properties such as ultra-sensitive, label-free, rapid, specific, and non-destructive detection processes. In this review, we summarized the progress in recent 10 years on SERS-based sensing of endogenous metabolites at the cellular level, in tissues, and in biofluids, as well as drug metabolites in biofluids. We made detailed discussions on the challenges and optimization methods of SERS technique in metabolite detection. The combination of SERS with modern biomedical technology were also anticipated.

show abstract

Section: Main Metabolic Molecules Detecting Methodsmentioning

confidence: 99%

Human metabolite detection by surface-enhanced Raman spectroscopy

Liu

2022

Materials Today Bio

View full text Add to dashboard Cite

show abstract

“…We envision that, in the near future, ncRNAs could achieve clinical use as biomarkers, most probably in combination with complementary methods—for example, in combination with circulating tumor cells, protein biomarkers, or even metabolites. 168 …”

Section: Future Perspectivesmentioning

confidence: 99%

Targeting non-coding RNAs to overcome cancer therapy resistance

Chen

Dragomir

Yang

et al. 2022

Sig Transduct Target Ther

Self Cite

167

View full text Add to dashboard Cite

It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts, are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are widely appreciated as pervasive regulators of multiple cancer hallmarks such as proliferation, apoptosis, invasion, metastasis, and genomic instability. Despite recent discoveries in cancer therapy, resistance to chemotherapy, radiotherapy, targeted therapy, and immunotherapy continue to be a major setback. Recent studies have shown that ncRNAs also play a major role in resistance to different cancer therapies by rewiring essential signaling pathways. In this review, we present the intricate mechanisms through which dysregulated ncRNAs control resistance to the four major types of cancer therapies. We will focus on the current clinical implications of ncRNAs as biomarkers to predict treatment response (intrinsic resistance) and to detect resistance to therapy after the start of treatment (acquired resistance). Furthermore, we will present the potential of targeting ncRNA to overcome cancer treatment resistance, and we will discuss the challenges of ncRNA-targeted therapy—especially the development of delivery systems.

show abstract

“…As a matter of fact, liquid biopsies have emerged as powerful diagnostic tools not only because of their advantages related to the reduction in invasiveness and risks for the patients but also because it is possible to discriminate between physiological and pathological conditions by precociously identifying analytes (chemicals, biomolecules, cells, etc.) at concentration down to picomolar (pM) [ 1 ]. To address this issue, analytical devices must be characterized by high specificity, high sensitivity, quickness, and accuracy.…”

Section: Introductionmentioning

confidence: 99%

Design and Synthesis of Novel Raman Reporters for Bioorthogonal SERS Nanoprobes Engineering

Dallari

Innocenti

Lenci

et al. 2022

IJMS

View full text Add to dashboard Cite

Surface-enhanced Raman spectroscopy (SERS) exploiting Raman reporter-labeled nanoparticles (RR@NPs) represents a powerful tool for the improvement of optical bio-assays due to RRs’ narrow peaks, SERS high sensitivity, and potential for multiplexing. In the present work, starting from low-cost and highly available raw materials such as cysteamine and substituted benzoic acids, novel bioorthogonal RRs, characterized by strong signal (103 counts with FWHM < 15 cm−1) in the biological Raman-silent region (>2000 cm−1), RRs are synthesized by implementing a versatile, modular, and straightforward method with high yields and requiring three steps lasting 18 h, thus overcoming the limitations of current reported procedures. The resulting RRs’ chemical structure has SH-pendant groups exploited for covalent conjugation to high anisotropic gold-NPs. RR@NPs constructs work as SERS nanoprobes demonstrating high colloidal stability while retaining NPs’ physical and vibrational properties, with a limit of detection down to 60 pM. RR@NPs constructs expose carboxylic moieties for further self-assembling of biomolecules (such as antibodies), conferring tagging capabilities to the SERS nanoprobes even in heterogeneous samples, as demonstrated with in vitro experiments by transmembrane proteins tagging in cell cultures. Finally, thanks to their non-overlapping spectra, we envision and preliminary prove the possibility of exploiting RR@NPs constructs simultaneously, aiming at improving current SERS-based multiplexing bioassays.

show abstract

SERS liquid biopsy: An emerging tool for medical diagnosis

Cited by 54 publications

References 89 publications

Human metabolite detection by surface-enhanced Raman spectroscopy

Human metabolite detection by surface-enhanced Raman spectroscopy

Targeting non-coding RNAs to overcome cancer therapy resistance

Design and Synthesis of Novel Raman Reporters for Bioorthogonal SERS Nanoprobes Engineering

Contact Info

Product

Resources

About